Registration Open / Visit Exhibits

Product Theatre Breakfast - Non-CME
hATTR Progression: Addressing Polyneuropathy
Supported by: AstraZeneca
Speaker: Dmitry Yaranov, MD

Introduction to the 29th Annual Symposium: Heart Failure 2025 – An Update on Therapy
Uri Elkayam, MD, FACC

Hyperlipidemia: An Update on Non-Statin Therapy
Pam Taub, MD

Evolving Strategies for the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors, When and How to Use Them
Michelle M. Kittleson, MD

Treating Congestion and Optimizing GDMP in the Hospitalized Patient with ADHF
Maria Rosa Costanzo, MD

Contemporary Drug Therapy for Patients with Heart Failure and Reduced Ejection Fraction
Akshay Desai, MD

Break/Visit Exhibits

KEYNOTE LECTURE
Advances In Gene Therapy For Treating Patients With Cardiomyopathy
Barry Greenberg, MD

How Do I Optimize Heart Failure Medications for Patients with Chronic and End Stage Kidney Disease?
Maria Rosa Costanzo, MD

The Contemporary Approach to the Management of Cardiogenic Shock
Nir Uriel, MD

HFpEF: Diagnostic Challenges and Pitfalls
Uri Elkayam, MD

Advances in Pharmacologic and Nonpharmacological Management of HFpEF
Akshay Desai, MD

Product Theatre Luncheon - Non-CME
Introduction to AMVUTTRA® (vutrisiran)
Supported by: Alnylam Pharmaceuticals
Speaker: Marcus Anthony Urey, MD

Break

Industry Session - Non-CME
Rethinking Hyperkalemia Management in Patients on RAAS Inhibitor Therapy
Supported by: AstraZeneca
Speaker: Ashish Brahmbhatt, PharmD

Break

Closing the Knowledge Gap On Diagnosis And Treatment Of Implantable Cardiac Device Infection In Heart Failure
Ulrika Birgersdotter-Green, MD

Tricuspid Regurgitation: Prevalence, Prognostic Implications and Emerging Therapy
Steve Burstein, MD

Management of Atrial Fibrillation in Patients Across the Spectrum of Heart Failure
Anil Bhandari, MD

Anti-Obesity Medications in Patients with Heart Failure: Current Evidence and Practical Guidance
Amanda R. Vest, MBBS, MPH

Break/Visit Exhibits

Beyond Medical Therapy - Carotid Baroreceptor Stimulation and Cardiac Contractility Modulation
Michael Fong, MD

Finerenone - A New Option for the Management of Heart Failure and Kidney Disease: Results of Clinical Trials and Implications for Therapy
Uri Elkayam, MD

What is New in the Management of Hypertension - Review of the 2024 ESC Guidelines
Vito Campese, MD

ATTR Amyloidosis: Current and Emerging Management Strategies
Mazen Hanna, MD

Pulmonary Arterial Hypertension: Introduction of New Therapy
Ron Oudiz, MD

The Potential Use Of AI In The Diagnosis And Management Of Heart Failure
Nir Uriel, MD

Adjourn